Paysign outlines 30%–35% revenue growth target for 2026 with continued margin expansion

Earnings Call Insights: Paysign, Inc. (PAYS) Q4 2025

MANAGEMENT VIEW

* Mark Newcomer, President and CEO, reported "continued strength and exceptional growth across all key metrics," noting full-year revenue increased 40.5% to $82 million, net income rose 98% to $7.6 million, and adjusted EBITDA grew 107% to $19.9 million. Operating margins increased by 723 basis points, signaling a key inflection point in profitability and operating leverage.
* Newcomer highlighted that the patient affordability business saw annual revenue grow 168% year-over-year to $33.9 million, with claims processed up approximately 79%. He stated the platform "helped deliver nearly $1 billion in financial assistance to patients" and that their dynamic business rules technology "saved our clients over $325 million" in 2025, with $150 million saved already in the current year.
* The company added 55 programs during the year, bringing total active programs to 131 and now works with 6 of the top 10 U.S. pharmaceutical manufacturers. Newcomer emphasized ongoing expansion within existing client relationships and a robust pipeline ahead of the Asembia Specialty Pharmacy Summit.
* Matthew Turner, President of Patient Affordability, addressed concerns over direct-to-consumer and pharmacy discount programs, stating these models are "not a meaningful substitute for our core business" and that "demand for our dynamic business rule solutions... continues to grow."
* On the plasma donor compensation business, Newcomer reported revenue of $45.6 million, up 4% year-over-year, with the company exiting 2025 with 595 centers and a market share just under 50%. He pointed to additional growth opportunities through donor management tools and anticipated FDA review of their donor management system.
* Jeffery Baker, CFO, stated, "total revenues increased 40.5% to $82 million. Pharma industry revenue increased 167.8% to $33.9 million," driven by "the addition of 55 net patient affordability programs launched during the past 12 months." He noted, "operating expenses were $41.4 million, an increase of 32.6%, well below the revenue growth we experienced," and "gross profit margin to 59.4% versus 55.1%." Baker highlighted cash balances of $21.1 million at year-end and zero bank debt.

OUTLOOK

* Baker indicated 2026 revenue guidance of $106.5 million to $110.5 million, representing 30% to 35% year-over-year growth, with plasma and pharma contributing equally and other revenue contributing $2.5 million. Gross profit margins are expected between 60% and 62%, and operating expenses are set to increase 20%. Net income is projected to nearly double over 2025, reaching $13 million to $16 million or $0.21 to $0.26 per diluted share. Adjusted EBITDA is forecast to be $30 million to $33 million or $0.49 to $0.53 per diluted share.
* For Q1 2026, projected revenue is $27 million to $27.5 million, with 137 active patient affordability programs and 589 plasma centers expected at quarter-end. Margins are forecast to expand, with operating margin between 20% to 22%, net margin 17% to 19%, and adjusted EBITDA margin 34.5% to 36.5%. Fully diluted EPS is estimated at $0.07 to $0.08.
* Baker noted, "our outlook reflects continued strong growth driven primarily by our patient affordability business, along with further margin expansion as we scale."

FINANCIAL RESULTS

* Revenues for 2025 were $82 million, a 40.5% year-over-year increase. Pharma industry revenue reached $33.9 million, up 167.8%, and plasma revenue was $45.6 million, up 4%. Operating expenses rose to $41.4 million, a 32.6% increase, while gross profit margin improved to 59.4%. Baker reported a year-end cash position of $21.1 million and highlighted zero bank debt. Fourth quarter earnings before taxes were $2.5 million, with adjusted EBITDA at $5.4 million or $0.09 per diluted share.

Q&A

* Jacob Stephan, Lake Street Capital Markets: Asked if pharma manufacturers are slowing initiatives. Turner responded, "I would argue that it's just the opposite.... I don't really see a slowdown."
* Stephan: Inquired about the GLP-1 opportunity. Turner stated, "we don't have any of the 2 larger GLP-1s... But yes, we're certainly trying to make inroads to get access to more of those programs."
* Stephan: Questioned fixed cost plateauing. Baker clarified, "the incremental costs that we have to add going forward as the business grows is certainly a lot less than what it has been historically."
* Gary Prestopino, Barrington Research: Confirmed Q1 targets—Baker replied, "Yes, that's correct," for 137 pharma programs and 589 plasma centers.
* Prestopino: Asked about revenue per claim differences. Turner explained, "profit potential and even bottom line margin is far superior in the specialty space."
* Peter Heckmann, D.A. Davidson: Asked about plasma guidance and growth. Baker replied, "My expectations haven't changed with plasma is that in a normalized year, it's about a 5% grower, and it's a very good cash cow."
* Heckmann: Sought FDA feedback on Nuvec system. Newcomer stated, "We expect to hear back from them within the next 60 days."
* Jon Hickman, Ladenburg Thalmann: Asked about pharma market TAM and growth stage. Turner estimated the TAM at $500 million to $850 million, possibly expanding to $1 billion, adding, "I think we're in the first inning."

SENTIMENT ANALYSIS

* Analysts raised questions about growth sustainability, GLP-1 market penetration, cost controls, and competitive threats, generally adopting a constructive but probing tone.
* Management maintained a confident and positive tone, highlighting operating leverage, innovation, and robust growth, with Turner asserting, "I don't really have any fears at the moment. It's all positive for us right now."
* Compared to the previous quarter, management’s tone is more assertive regarding the durability and scalability of patient affordability, while analysts’ tone remains focused on understanding growth levers, cost structure, and competitive differentiation.

QUARTER-OVER-QUARTER COMPARISON

* Compared to Q3 2025, Paysign reported accelerated full-year growth and a significant jump in patient affordability revenue. The number of active patient affordability programs rose from 105 at Q3-end to 131 by year-end. Gross profit margin improved from 56.3% in Q3 to 59.4% for the full year. Operating leverage became more evident, with a notable increase in operating margin.
* Guidance language shifted from "raising our revenue guidance" in Q3 to providing detailed 2026 and Q1 outlooks, emphasizing margin expansion alongside topline growth. Analysts continued to focus on revenue mix, scalability, and program profitability.
* Management sentiment grew more confident regarding the scalability of the patient affordability business and the durability of demand, while analyst tone remained neutral to slightly positive, with persistent questions about new market opportunities and cost structure.

RISKS AND CONCERNS

* Management addressed potential threats from DTC and pharmacy discount programs, concluding these are not relevant to their core business. Turner emphasized, "we do not view these dynamics as a material threat to our business."
* Legislative and regulatory risks were discussed, with Turner stating, "there has been no meaningful federal action to date nor do we expect any in the foreseeable future" related to accumulator and maximizer programs.
* Baker acknowledged investor concerns about the newness of the patient affordability business model in public markets, but pointed to "operating margin goes from 1.7% to 9%, and that's not insignificant."
* On competitive threats, Turner noted, "there's some new players popping up... I would say the good thing for us is we were ahead of that, and we also helped to cause a lot of the disruption."

FINAL TAKEAWAY

Paysign management emphasized that 2025 marked an inflection point as the patient affordability business scaled and delivered strong revenue growth, margin expansion, and operating leverage. The company expects continued momentum into 2026, driven by robust demand, a growing program base, and sustained investments in technology and personnel, positioning Paysign to capture further share and deliver meaningful profitability gains.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/pays/earnings/transcripts]

MORE ON PAYSIGN

* Paysign, Inc. (PAYS) Q4 2025 Earnings Call Transcript [https://seekingalpha.com/article/4885540-paysign-inc-pays-q4-2025-earnings-call-transcript]
* Paysign, Inc. (PAYS) Presents at Oppenheimer 11th Annual Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4865126-paysign-inc-pays-presents-at-oppenheimer-11th-annual-emerging-growth-conference-slideshow]
* Paysign GAAP EPS of $0.02 in-line, revenue of $22.76M beats by $1.21M [https://seekingalpha.com/news/4568204-paysign-gaap-eps-of-0_02-in-line-revenue-of-22_76m-beats-by-1_21m]
* Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag [https://seekingalpha.com/news/4566972-quant-snapshot-aar-noah-holdings-lead-strong-buys-as-blaize-fractyl-health-lag]
* Seeking Alpha’s Quant Rating on Paysign [https://seekingalpha.com/symbol/PAYS/ratings/quant-ratings]